Skip to search formSkip to main contentSkip to account menu

canakinumab

Known as: immunoglobulin G1, anti-(human interleukin 1beta) (human clone ACZ885 heavy chain V region) 
A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab… 
National Institutes of Health

Related topics

Related topics

5 relations
1 ML canakinumab 150 MG/ML Injection [Ilaris]antigen bindingcanakinumab 180 MG Injection [Ilaris]

Narrower (1)

ACZ885

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
2417Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab
The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) established that targeting inflammation with… 
2018
2018
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.
Review
2018
Review
2018
Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients
Objective We aimed to present our single-center real-life experience of canakinumab use in adult patients with familial… 
2017
2017
Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
OBJECTIVES To assess the long-term safety and efficacy of canakinumab in Japanese patients with cryopyrin-associated periodic… 
Review
2015
Review
2015
Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
Abstract Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited… 
Review
2014
Review
2014
Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) previously published an article in Arthritis Care & Research… 
Review
2013
Review
2013
Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
The cryopyrin-associated periodic syndrome (CAPS) is a very rare disease. It is estimated that there are 1–2 cases for every 1… 
Review
2013
Review
2013
Targeting the unstable plaque in acute coronary syndromes.
2011
2011
The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis
Self-limited, non-destructive arthritis is a common clinical presentation of familial Mediterranean fever (FMF), while protracted… 
Review
2010
Review
2010
Canakinumab for treatment of cryopyrin-associated periodic syndrome
Importance of the field: Autoinflammatory syndromes such as cryopyrin-associated periodic syndromes (CAPS) place a heavy burden… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)